{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:26:12Z","timestamp":1790033172638,"version":"4.0.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014421","name":"EA Pharma Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EPS International Holdings Co., Ltd"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 103 patients with serum HBsAg levels of \u2265100 IU\/mL who had received ETV were enrolled. The nucleos(t)ide analog used for the treatment was switched from ETV to TAF, and the changes in serum HBsAg levels during the 144-week period before and after the drug switching were compared in 74 patients who had received ETV at least for 192 weeks.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Significant decreases of serum HBsAg levels were observed during both the ETV and the TAF administration period, although the degree of reduction was greater during the latter period than during the former period (P&lt;0.001). Significant decreases of serum HBsAg levels were seen in both patients with genotype B HBV infection and genotype C HBV infection, irrespective of the serum HBsAg and HBcrAg levels at the time of the drug switching.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Switching of the nucleos(t)ide analog used for treatment from ETV to TAF merits consideration in patients with chronic HBV infection, since the extent of reduction of the serum HBsAg level was greater during the TAF treatment period than during the ETV treatment period.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0262764","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T18:27:44Z","timestamp":1645208864000},"page":"e0262764","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-0915","authenticated-orcid":true,"given":"Yoshihito","family":"Uchida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Kouyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Tomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-4526","authenticated-orcid":true,"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"pone.0262764.ref001","unstructured":"National Cancer Center, Cancer Information Service. Cancer incidence and incidence rates in Japan in 2019. https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html. Updated at 10th February 2021."},{"key":"pone.0262764.ref002","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00535-018-1532-5","article-title":"A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011\u20132015 update","volume":"54","author":"R Tateishi","year":"2019","journal-title":"J Gastroenterol"},{"key":"pone.0262764.ref003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"CJ Chen","year":"2006","journal-title":"JAMA"},{"key":"pone.0262764.ref004","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"TC Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"pone.0262764.ref005","unstructured":"JSH guidelines for the management of hepatitis B infection. Ver3.3, 2021 January, https:\/\/www.jsh.or.jp\/medical\/guidelines\/jsh_guidelines\/HBV_GL_ver3.3.pdf."},{"key":"pone.0262764.ref006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of Tenofovir Disoproxil Fumarate and Peginterferon \u03b1-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B","volume":"150","author":"P Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"pone.0262764.ref007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hepr.12902","article-title":"Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-na\u00efve chronic hepatitis B patients","volume":"48","author":"K Koike","year":"2018","journal-title":"Hepatol Res"},{"key":"pone.0262764.ref008","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial","volume":"1","author":"HL Chen","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0262764.ref009","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-negative chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial","volume":"1","author":"M Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0262764.ref010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis bvirus infection","volume":"68","author":"K Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0262764.ref011","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jmv.25644","article-title":"Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate","volume":"92","author":"Y Uchida","year":"2020","journal-title":"J Med Virol"},{"key":"pone.0262764.ref012","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load","volume":"40","author":"T Kimura","year":"2002","journal-title":"J Clin Microbiol"},{"key":"pone.0262764.ref013","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"S Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"pone.0262764.ref014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00535-018-1502-y","article-title":"Long-term outcome of entecavir treatment of nucleos(t)ide analogue-na\u00efve chronic hepatitis B patients in Japan","volume":"54","author":"F Suzuki","year":"2019","journal-title":"J Gastroenterol"},{"key":"pone.0262764.ref015","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.ijo.0803479","article-title":"Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?","volume":"31","author":"CM Chu","year":"2007","journal-title":"Int J Obes (Lond)"},{"key":"pone.0262764.ref016","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MEG.0000000000001733","article-title":"Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels","volume":"32","author":"T Kumada","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"pone.0262764.ref017","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"E Ogawa","year":"2020","journal-title":"Liver Int"},{"key":"pone.0262764.ref018","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jmv.25515","article-title":"Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B","volume":"91","author":"S Hagiwara","year":"2019","journal-title":"J Med Virol"},{"key":"pone.0262764.ref019","article-title":"Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long-term effects from a prospective study","author":"S Hagiwara","year":"2021","journal-title":"Hepatol Res"},{"key":"pone.0262764.ref020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jgh3.12443","article-title":"Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B","volume":"5","author":"N Itokawa","year":"2020","journal-title":"JGH Open"},{"key":"pone.0262764.ref021","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","author":"ZB Li","year":"2021","journal-title":"Liver Int"},{"key":"pone.0262764.ref022","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/jgh3.12273","article-title":"Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir","volume":"4","author":"N Tamaki","year":"2019","journal-title":"JGH Open"},{"key":"pone.0262764.ref023","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"K Murata","year":"2018","journal-title":"Gut"},{"issue":"5","key":"pone.0262764.ref024","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep.30956","article-title":"Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection","volume":"71","author":"K Murata","year":"2020","journal-title":"Hepatology"},{"key":"pone.0262764.ref025","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.2147\/DDDT.S274307","article-title":"The effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on liver enzymes, glucose, and lipid profile","volume":"14","author":"N Squillace","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"pone.0262764.ref026","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/hiv.12840","article-title":"Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?","volume":"21","author":"C Schwarze-Zander","year":"2020","journal-title":"HIV Med"},{"key":"pone.0262764.ref027","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00535-020-01750-3","article-title":"Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection","volume":"56","author":"K Suzuki","year":"2021","journal-title":"J Gastroenterol"},{"key":"pone.0262764.ref028","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV: A Cohort Study","volume":"174","author":"B Surial","year":"2021","journal-title":"Ann Intern Med"},{"key":"pone.0262764.ref029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China","volume":"158","author":"Yip TCF","year":"2020","journal-title":"Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T18:28:09Z","timestamp":1645208889000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262764"}},"subtitle":[],"editor":[{"given":"Jee-Fu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262764","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]}}}